197 related articles for article (PubMed ID: 38192023)
21. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
22. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes.
Liu D; Shoag JE; Poliak D; Goueli RS; Ravikumar V; Redmond D; Vosoughi A; Fontugne J; Pan H; Lee D; Thomas D; Salari K; Wang Z; Romanel A; Te A; Lee R; Chughtai B; Olumi AF; Mosquera JM; Demichelis F; Elemento O; Rubin MA; Sboner A; Barbieri CE
Nat Commun; 2020 Apr; 11(1):1987. PubMed ID: 32332823
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.
Hasby EA; Saied EM
J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472
[TBL] [Abstract][Full Text] [Related]
24. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
van Vuuren SP; Heyns CF; Zarrabi AD
BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
[TBL] [Abstract][Full Text] [Related]
25. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
26. Apoptotic versus proliferative activities in human benign prostatic hyperplasia.
Kyprianou N; Tu H; Jacobs SC
Hum Pathol; 1996 Jul; 27(7):668-75. PubMed ID: 8698310
[TBL] [Abstract][Full Text] [Related]
27. Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts.
Prajapati A; Gupta S; Mistry B; Gupta S
Biomed Res Int; 2013; 2013():107954. PubMed ID: 23936768
[TBL] [Abstract][Full Text] [Related]
28. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma.
Cordon-Cardo C; Koff A; Drobnjak M; Capodieci P; Osman I; Millard SS; Gaudin PB; Fazzari M; Zhang ZF; Massague J; Scher HI
J Natl Cancer Inst; 1998 Sep; 90(17):1284-91. PubMed ID: 9731735
[TBL] [Abstract][Full Text] [Related]
29. Distinctive gene expression of prostatic stromal cells cultured from diseased versus normal tissues.
Zhao H; Ramos CF; Brooks JD; Peehl DM
J Cell Physiol; 2007 Jan; 210(1):111-21. PubMed ID: 17044071
[TBL] [Abstract][Full Text] [Related]
30. The role of FASL, BCL-2 and BAX polymorphisms in brazilian patients with prostate cancer and benign prostatic hyperplasia.
da Silva Lawisch GK; Biolchi V; Kaufmann G; Nicolai G; Capitaneo E; Rosembach TR; Zang J; Brum IS; Chies JAB
Mol Biol Rep; 2022 Oct; 49(10):9445-9451. PubMed ID: 35988104
[TBL] [Abstract][Full Text] [Related]
31. Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population.
Petrovics G; Price DK; Lou H; Chen Y; Garland L; Bass S; Jones K; Kohaar I; Ali A; Ravindranath L; Young D; Cullen J; Dorsey TH; Sesterhenn IA; Brassell SA; Rosner IL; Ross D; Dahut W; Ambs S; Figg WD; Srivastava S; Dean M
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):406-410. PubMed ID: 30542053
[TBL] [Abstract][Full Text] [Related]
32. Psoralea corylifolia L. extract ameliorates benign prostatic hyperplasia by regulating prostate cell proliferation and apoptosis.
Kim HJ; Jin BR; An HJ
J Ethnopharmacol; 2021 Jun; 273():113844. PubMed ID: 33485982
[TBL] [Abstract][Full Text] [Related]
33. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
[TBL] [Abstract][Full Text] [Related]
34. No Tumor Suppressor Role for
Koseoglu H; Celebi A; Galamiyeva G; Dalay N; Ozkardes H; Buyru N
DNA Cell Biol; 2021 Sep; 40(9):1222-1229. PubMed ID: 34370601
[TBL] [Abstract][Full Text] [Related]
35. Ser217Leu polymorphism of the HPC2/ELAC2 gene associated with prostatic cancer risk in Japanese men.
Takahashi H; Lu W; Watanabe M; Katoh T; Furusato M; Tsukino H; Nakao H; Sudo A; Suzuki H; Akakura K; Ikemoto I; Asano K; Ito T; Wakui S; Muto T; Hano H
Int J Cancer; 2003 Nov; 107(2):224-8. PubMed ID: 12949798
[TBL] [Abstract][Full Text] [Related]
36. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis.
Luo J; Dunn T; Ewing C; Sauvageot J; Chen Y; Trent J; Isaacs W
Prostate; 2002 May; 51(3):189-200. PubMed ID: 11967953
[TBL] [Abstract][Full Text] [Related]
37. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.
Habuchi T; Liqing Z; Suzuki T; Sasaki R; Tsuchiya N; Tachiki H; Shimoda N; Satoh S; Sato K; Kakehi Y; Kamoto T; Ogawa O; Kato T
Cancer Res; 2000 Oct; 60(20):5710-3. PubMed ID: 11059764
[TBL] [Abstract][Full Text] [Related]
38. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
39. Two long non-coding RNAs, Prcat17.3 and Prcat38, could efficiently discriminate benign prostate hyperplasia from prostate cancer.
Bayat H; Narouie B; Ziaee SM; Mowla SJ
Prostate; 2018 Aug; 78(11):812-818. PubMed ID: 29671889
[TBL] [Abstract][Full Text] [Related]
40. PTPIP51 mRNA and protein expression in tissue microarrays and promoter methylation of benign prostate hyperplasia and prostate carcinoma.
Koch P; Petri M; Paradowska A; Stenzinger A; Sturm K; Steger K; Wimmer M
Prostate; 2009 Dec; 69(16):1751-62. PubMed ID: 19691131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
